Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Haidilao (6862): A Recovery Is on the Way

Haidilao (海底捞) Placement - Founders Back to Sell More

Super Hi Spin-Off: Unexciting Fundamentals

Trade Ideas: China Showing Signs of Recovering While the Rest of the World Slows Down

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

COVID-19: Alternative Data Update, China Close To Normal While Other Global Cities Grind To A Halt

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Haidilao International Holding / Equity Capital Markets

<p>Bankers launched a USD 200 million placement today to sell 47 million shares for the company. In this insight, we will provide a quick analysis of the deal term and our thoughts. We are of the view that the strong share price performance recently has provided a good selling opportunity for the company's founder in the post-Covid-19 era. We are of the view that the sell down overhang will last long after today's placement and hence capped the share performance in the long run. </p>

Bankers launched a USD 200 million placement today to sell 47 million shares for the company. In this insight, we will provide a quick analysis of the deal term and our thoughts. We are of the view that the strong share price performance recently has provided a good selling opportunity for the company's founder in the post-Covid-19 era. We are of the view that the sell down overhang will last long after today's placement and hence capped the share performance in the long run. 

Haidilao Placement: Concerted Founders' Sell Down at Right Time?